Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis

Roesel, Martin; Tappeiner, Christoph; Heiligenhaus, Arnd; Heinz, Carsten (2011). Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis. Clinical ophthalmology, 5, pp. 1309-1313. Auckland (NZ): Dove Medical Press 10.2147/OPTH.S11125

Full text not available from this repository. (Request a copy)

Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, was developed to prevent organ graft rejection and to treat autoimmune diseases. The chemical structure of voclosporin is similar to that of cyclosporine A, with a difference in one amino acid, leading to superior calcineurin inhibition and less variability in plasma concentration. Compared with placebo, voclosporin may significantly reduce inflammation and prevent recurrences of inflammation in patients with noninfectious uveitis. Future studies have to show if these advantages are accompanied by greater clinical efficacy and fewer side effects compared with the classic calcineurin inhibitors.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Tappeiner, Christoph




Dove Medical Press




Christoph Tappeiner

Date Deposited:

04 Oct 2013 14:23

Last Modified:

08 Jun 2016 10:26

Publisher DOI:


PubMed ID:



https://boris.unibe.ch/id/eprint/8122 (FactScience: 213607)

Actions (login required)

Edit item Edit item
Provide Feedback